Skip to main content

Day: September 28, 2020

Volcanic Announces $5 Million Bought Deal Offering

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATESVANCOUVER, British Columbia, Sept. 28, 2020 (GLOBE NEWSWIRE) — Volcanic Gold Mines Inc. (TSXV: VG), (“Volcanic” or the “Company”) is pleased to announce that it has entered into an agreement with Haywood Securities Inc. to act as lead underwriter, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 9,100,000 units of the Company (the “Units”), at a price of C$0.55 per Unit (the “Offering Price”) for gross proceeds to the Company of C$5,005,000 (the “Offering”).Each Unit will consist of one common share in the capital of the Company (a “Common...

Continue reading

Scorpio Bulkers Inc. Announces the Sale of a Kamsarmax Vessel

MONACO, Sept. 28, 2020 (GLOBE NEWSWIRE) — Scorpio Bulkers, Inc. (NYSE: SALT) (the “Company”) announced today that the Company has entered into an agreement with an unaffiliated third party to sell the SBI Rock, a 2016 built non-scrubber-fitted Kamsarmax vessel, for a price slightly in excess of $18 million. Delivery of the vessel is expected to take place in the fourth quarter of 2020. The sale is expected to generate additional liquidity of approximately $5 million.  In addition, the Company will save approximately $1 million in budgeted drydocking costs during the first quarter of 2021.Emanuele Lauro, Chairman and CEO, commented “Last month we announced a new direction for Scorpio Bulkers- offshore wind as a sustainable business opportunity.   This sale represents a step, one of the many deliberate steps we must take, in our transition.”About...

Continue reading

Beam Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Sept. 28, 2020 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines though base-editing, announced today the commencement of a proposed public offering of 4,500,000 shares of its common stock. All of the shares will be offered by Beam. Beam also expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock.J.P. Morgan, Jefferies and Barclays are acting as joint book-running managers for the proposed offering. Wedbush PacGrow is acting as lead manager for the proposed offering.A registration statement on Form S-1 relating to the securities being sold in this offering has been filed with the Securities and Exchange Commission (the “SEC”) but has not yet been declared effective. Before you invest,...

Continue reading

Tonix Pharmaceuticals Completes Purchase of Facility to House Advanced Development Center (ADC) for Vaccine Programs

Facility Addresses the Shortage of Vaccine Production Capacity in the U.S.When Fully Operational the ADC Is Expected to be Capable of Manufacturing Clinical Trial Quality Vaccines, Including Vaccines Under Development for COVID-19CHATHAM, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, completed the purchase a 40,000 square foot facility in Massachusetts to house its new Advanced Development Center (ADC) for accelerated development and manufacturing of vaccines, including vaccines for COVID-19.Tonix expects the facility to be operational within 24 months with single-use bioreactors and purification suites with equipment for Good Manufacturing Practice production of vaccines for clinical trials, including when fully operational,...

Continue reading

Questor Announces New Chief Operating Officer

CALGARY, Alberta, Sept. 28, 2020 (GLOBE NEWSWIRE) — Questor Technology Inc., a global leader in the clean combustion of waste gas streams, is pleased to announced that Darko Ulakovic has joined the company as Chief Operating Officer.Darko brings a wealth of experience to our team with a strong track record of successful scaling up companies and growing revenue. CEO Audrey Mascarenhas commented, “Darko, has been instrumental in leading international sales growth, manufacturing, and supply chain development resulting in sustainable expansion and diversification. Darko is the right person help our team to take Questor through the next phase of its growth and development.”Darko brings over 20 years of experience in scaling manufacturing capabilities, streamlining operations, and increasing global and regional market share. Before joining...

Continue reading

Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) Acquires U.S. Patent and International Patent Applications to Produce Specialized Synthetic Nicotine Cessation Products

GRANT, Fla., Sept. 28, 2020 (GLOBE NEWSWIRE) — via NetworkWire – Kaival Brands Innovations Group, Inc. (OTCQB: KAVL) (“Kaival Brands,” the “Company,” or “we”), a company focused on growing and incubating innovative and profitable products into mature, dominant brands, is proud to announce its entry into a Patent Contribution Agreement (the “Agreement”), in which the Company will acquire exclusive rights to an international patent portfolio concerning full customization of certain isomeric properties of synthetic nicotine. Kaival Brands is also pleased to announce the formation of a new wholly-owned subsidiary, Kaival Labs, Inc., a Delaware corporation (“Kaival Labs”), that will own and develop the patent.The U.S. patent and international patent applications protect the utilization and creation of controlled preparations of synthetic...

Continue reading

VVC Announces New Private Placement Closing, Debt Conversion, Acquisition of Samalayuca Shares and Grant of Options

TORONTO, Sept. 28, 2020 (GLOBE NEWSWIRE) — VVC Exploration Corporation (“VVC” or the “Company”) (TSX-V:VVC) announces the following:Q2 FinancialsThe Company’s unaudited Financials for the Quarter Ended July 31, 2020 and the accompanying Management’s Discussion and Analysis were filed on SEDAR on September 25 and will be uploaded to the Company’s website.Private Placement FinancingVVC has closed subscriptions on a non-brokered private placement of units of the Company at a price of CA$0.05 per Unit, whereby each Unit consists of one common share (“Share”) and one common share purchase warrant (“Warrant”) entitling the holder to purchase one additional Share of the Company for a period of three years from Closing, at an exercise price of CA$0.075 per share. Aggregate...

Continue reading

Altera Infrastructure Announces Securities Repurchase Program

PEMBROKE, Bermuda, Sept. 28, 2020 (GLOBE NEWSWIRE) — Altera Infrastructure GP LLC (ALIN GP), the general partner of Altera Infrastructure L.P. (Altera Infrastructure or the Partnership), today announced its board of directors (the Board) has authorized repurchases of the Partnership’s outstanding 8.50% Senior Notes due 2023 and Series A, B and E Preferred Units through open market purchases, privately negotiated transactions and/or pursuant to Rule 10b5-1 plans, in compliance with applicable securities laws and other legal requirements. The timing, volume, and nature of any repurchases will be determined by management, in consultation with the Board, based on evaluation of the capital needs of the business, trading prices, applicable legal requirements, and other factors. The Partnership currently expects to fund the repurchase...

Continue reading

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol

ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patient cycle of diet, exercise and a statin treatment without ever reaching guideline recommended cholesterol levels. Approved earlier this year by the U.S. Food and Drug Administration (FDA) and launched at the height of the COVID-19 pandemic, NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering medicine available to indicated patients in nearly 20 years.NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic...

Continue reading

Sonoco Again Named a “Best for Vets” Company

HARTSVILLE, S.C., Sept. 28, 2020 (GLOBE NEWSWIRE) — Sonoco (NYSE: SON), one of the largest global diversified packaging companies, has once again been named one of 100 “Best for Vets” companies by Military Times. Sonoco joins other well-known brands, including Kellogg Company, Amazon, Deloitte and L’Oréal USA on the distinguished list.“Our Veterans are some of our brightest and hardworking associates,” said Howard Coker, president and CEO. “They bring specific attributes that align with our mantra of ‘People Build Businesses by Doing the Right Thing,’ including loyalty, teamwork and determination. We are proud to be included on such a distinguished list.”Representing the most prominent annual public rankings of its kind, Best for Vets evaluates companies’ cultures, veteran recruiting, veteran policies and accommodations for members...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.